{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:27:16Z","timestamp":1766158036229},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T00:00:00Z","timestamp":1484870400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"AbbVie Corporation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s00431-017-2849-4","type":"journal-article","created":{"date-parts":[[2017,1,20]],"date-time":"2017-01-20T02:51:13Z","timestamp":1484880673000},"page":"413-422","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005\u20132015)"],"prefix":"10.1007","volume":"176","author":[{"name":"CARESS Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Y.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abby","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bosco","family":"Paes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista L.","family":"Lanct\u00f4t","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,20]]},"reference":[{"key":"2849_CR1","first-page":"609","volume-title":"Red book: 2012 report of the Committee of Infectious Diseases","author":"American Academy of Pediatrics","year":"2012","unstructured":"American Academy of Pediatrics (2012) Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS (eds) Red book: 2012 report of the Committee of Infectious Diseases. Elk Grove Village, Illinois, pp 609\u2013618"},{"key":"2849_CR2","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics Committee on Infectious Diseases (2014) Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics 134: 415-420","DOI":"10.1542\/peds.2014-1665"},{"key":"2849_CR3","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2191-1991-3-18","volume":"3","author":"A Bentley","year":"2013","unstructured":"Bentley A, Filipovic I, Gooch K, B\u00fcsch K (2013) A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. Health Econ Rev 3:18","journal-title":"Health Econ Rev"},{"key":"2849_CR4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12016-013-8368-9","volume":"45","author":"AT Borchers","year":"2013","unstructured":"Borchers AT, Chang C, Gershwin ME, Gershwin LJ (2013) Respiratory syncytial virus\u2014a comprehensive review. Clin Rev Allergy Immunol 45:331\u2013379","journal-title":"Clin Rev Allergy Immunol"},{"key":"2849_CR5","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1067\/mpd.2000.110531","volume":"137","author":"TG Boyce","year":"2000","unstructured":"Boyce TG, Mellen BG, Mitchel EF, Wright PF, Griffin MR (2000) Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 137:865\u2013870","journal-title":"J Pediatr"},{"key":"2849_CR6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/adc.2005.087270","volume":"91","author":"S Broughton","year":"2006","unstructured":"Broughton S, Bhat R, Roberts A, Zuckerman M, Rafferty G, Greenough A (2006) Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants. Arch Dis Child 91:26\u201330","journal-title":"Arch Dis Child"},{"key":"2849_CR7","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00006454-200007000-00002","volume":"19","author":"X Carbonell-Estrany","year":"2000","unstructured":"Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Dom\u00e9nech E, Figueras-Aloy J, Fraga JM, Garc\u00eda LG, Garc\u00eda-Alix A, Del R\u00edo MG et al (2000) Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33\u00a0weeks of gestation: a prospective study. IRIS Study Group. Pediatr Infect Dis J 19:592\u2013597","journal-title":"Pediatr Infect Dis J"},{"key":"2849_CR8","doi-asserted-by":"crossref","first-page":"e290","DOI":"10.1097\/INF.0000000000000922","volume":"34","author":"P Chan","year":"2015","unstructured":"Chan P, Li A, Paes B, Abraha H, Mitchell I, Lanct\u00f4t KL, CARESS investigators (2015) Adherence to palivizumab for respiratory syncytial virus prevention in the Canadian registry of palivizumab. Pediatr Infect Dis J 34:e290\u2013e297","journal-title":"Pediatr Infect Dis J"},{"key":"2849_CR9","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3346\/jkms.2010.25.2.251","volume":"25","author":"SG Chang","year":"2010","unstructured":"Chang SG, Park MS, Yu JE (2010) Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009. J Korean Med Sci 25:251\u2013256","journal-title":"J Korean Med Sci"},{"key":"2849_CR10","doi-asserted-by":"crossref","first-page":"e0134711","DOI":"10.1371\/journal.pone.0134711","volume":"10","author":"JJ Chen","year":"2015","unstructured":"Chen JJ, Chan P, Paes B, Mitchell I, Li A, Lanct\u00f4t KL, CARESS investigators (2015) Serious adverse events in the Canadian registry of children receiving palivizumab (CARESS) for respiratory syncytial virus prevention. PLoS One 10:e0134711","journal-title":"PLoS One"},{"key":"2849_CR11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1542\/peds.2014-1665","volume":"134","author":"Committee On Infectious Diseases","year":"2014","unstructured":"Committee On Infectious Diseases, Bronchiolitis Guidelines Committee (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134:415\u2013420","journal-title":"Pediatrics"},{"key":"2849_CR12","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00431-014-2343-1","volume":"173","author":"SB Drysdale","year":"2014","unstructured":"Drysdale SB, Lo J, Prendergast M, Alcazar M, Wilson T, Zuckerman M, Smith M, Broughton S, Rafferty GF, Peacock JL et al (2014) Lung function of preterm infants before and after viral infections. Eur J Pediatr 173:1497\u20131504","journal-title":"Eur J Pediatr"},{"key":"2849_CR13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1164\/rccm.200703-476OC","volume":"176","author":"L Friedrich","year":"2007","unstructured":"Friedrich L, Pitrez PMC, Stein RT, Goldani M, Tepper R, Jones MH (2007) Growth rate of lung function in healthy preterm infants. Am J Respir Crit Care Med 176:1269\u20131273","journal-title":"Am J Respir Crit Care Med"},{"key":"2849_CR14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/jp.2008.28","volume":"28","author":"M Frogel","year":"2008","unstructured":"Frogel M, Nerwen C, Cohen A, VaVeldhuisen P, Harrington M, Boron M (2008) Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 28:511\u2013517","journal-title":"J Perinatol"},{"key":"2849_CR15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/thx.2008.095547","volume":"64","author":"A Greenough","year":"2009","unstructured":"Greenough A, Alexander J, Boit P, Boorman J, Burgess S, Burke A, Chetcuti PA, Cliff I, Lenney W, Lytle T et al (2009) School age outcome of hospitalisation with respiratory syncytial virus infection of prematurely born infants. Thorax 64:490\u2013495","journal-title":"Thorax"},{"key":"2849_CR16","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3346\/jkms.2015.30.7.924","volume":"30","author":"YM Han","year":"2015","unstructured":"Han YM, Seo HJ, Choi SH, Jung YJ, Ahn SY, Yoo HS, Sung SI, Shim JW, Lee YK, Ko SY et al (2015) Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia. J Korean Med Sci 30:924\u2013931","journal-title":"J Korean Med Sci"},{"key":"2849_CR17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1017\/S0950268815003015","volume":"144","author":"N Homaira","year":"2016","unstructured":"Homaira N, Oei JL, Mallitt KA, Abdel-Latif ME, Hilder L, Bajuk B, Lui K, Ferson M, Nurkic A, Chambers GM et al (2016) High burden of RSV hospitalization in very young children: a data linkage study. Epidemiol Infect 144:1612\u20131621","journal-title":"Epidemiol Infect"},{"key":"2849_CR18","doi-asserted-by":"crossref","first-page":"571609","DOI":"10.1155\/2014\/571609","volume":"2014","author":"N Homaira","year":"2014","unstructured":"Homaira N, Rawlinson W, Snelling TL, Jaffe A (2014) Effectiveness of palivizumab in preventing RSV hospitalization in high risk children: a real-world perspective. Int J Pediatr 2014:571609","journal-title":"Int J Pediatr"},{"key":"2849_CR19","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.pupt.2013.03.007","volume":"26","author":"WV La Via","year":"2013","unstructured":"La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ (2013) Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther 26:666\u2013671","journal-title":"Pulm Pharmacol Ther"},{"key":"2849_CR20","doi-asserted-by":"crossref","first-page":"S104","DOI":"10.3346\/jkms.2015.30.S1.S104","volume":"30","author":"JH Lee","year":"2015","unstructured":"Lee JH, Kim CS, Chang YS, Choi J, Committee on Data Collection and Statistical Analysis of the Korean Society of Neonatology (2015) Respiratory syncytial virus related readmission in preterm infants less than 34\u00a0weeks\u2019 gestation following discharge from a neonatal intensive care unit in Korea. J Korean Med Sci 30:S104\u2013S110","journal-title":"J Korean Med Sci"},{"key":"2849_CR21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s00431-002-1105-7","volume":"162","author":"JG Liese","year":"2003","unstructured":"Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH, The Munich RSV Study Group (2003) Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 162:230\u2013236","journal-title":"Eur J Pediatr"},{"key":"2849_CR22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095\u20132128","journal-title":"Lancet"},{"key":"2849_CR23","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jpeds.2012.09.042","volume":"162","author":"C McEvoy","year":"2013","unstructured":"McEvoy C, Venigalla S, Schilling D, Clay N, Spitale P, Nguyen T (2013) Respiratory function in healthy late preterm infants delivered at 33\u201336\u00a0weeks of gestation. J Pediatr 162:464\u2013469","journal-title":"J Pediatr"},{"key":"2849_CR24","doi-asserted-by":"crossref","first-page":"917068","DOI":"10.1155\/2013\/917068","volume":"2013","author":"B Paes","year":"2013","unstructured":"Paes B, Mitchell I, Li A, Harimoto T, Lanct\u00f4t KL (2013) Respiratory-related hospitalizations following prophylaxis in the Canadian registry for palivizumab (2005-2012) compared to other international registries. Clin Dev Immunol 2013:917068","journal-title":"Clin Dev Immunol"},{"key":"2849_CR25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00431-011-1654-8","volume":"171","author":"B Paes","year":"2012","unstructured":"Paes B, Mitchell I, Li A, Lanct\u00f4t KL (2012) Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr 171:833\u2013841","journal-title":"Eur J Pediatr"},{"key":"2849_CR26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/01.inf.0000086403.50417.7c","volume":"22","author":"C Pedraz","year":"2003","unstructured":"Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, Quero J, IRIS Study Group (2003) Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J 22:823\u2013827","journal-title":"Pediatr Infect Dis J"},{"key":"2849_CR27","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1513\/AnnalsATS.201504-218OC","volume":"12","author":"BB Poindexter","year":"2015","unstructured":"Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, Reynolds AM, Shaw PA, Jobe AH, Prematurity and Respiratory Outcomes Program (2015) Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc 12:1822\u20131830","journal-title":"Ann Am Thorac Soc"},{"key":"2849_CR28","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/ppul.22633","volume":"48","author":"S Ricart","year":"2013","unstructured":"Ricart S, Marcos MA, Sarda M, Anton A, Mu\u00f1oz-Almagro C, Pumarola T, Pons M, Garcia-Garcia JJ (2013) Clinical risk factors are more relevant than respiratory viruses in predicting bronchiolitis severity. Pediatr Pulmonol 48:456\u2013463","journal-title":"Pediatr Pulmonol"},{"key":"2849_CR29","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1128\/AAC.06446-11","volume":"56","author":"GJ Robbie","year":"2012","unstructured":"Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK (2012) Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 56:4927\u20134936","journal-title":"Antimicrob Agents Chemother"},{"key":"2849_CR30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/pch\/20.8.463a","volume":"20","author":"JL Robinson","year":"2015","unstructured":"Robinson JL, Le SN, Canadian Paediatric Society, Infectious Diseases and Immunization Committee (2015) Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health 20:321\u2013326","journal-title":"Paediatr Child Health"},{"key":"2849_CR31","first-page":"769","volume":"56","author":"AL Rogovik","year":"2010","unstructured":"Rogovik AL, Carleton B, Solimano A, Goldman R (2010) Palivizumab for the prevention of respiratory syncytial virus infection. Can Fam Physician 56:769\u2013772","journal-title":"Can Fam Physician"},{"key":"2849_CR32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1093\/pch\/14.8.521","volume":"14","author":"L Samson","year":"2009","unstructured":"Samson L, Canadian Paediatric Society, Infectious Diseases and Immunization Committee (2009) Prevention of respiratory syncytial virus infection. Paediatr Child Health 14:521\u2013526","journal-title":"Paediatr Child Health"},{"key":"2849_CR33","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1053\/rmed.2002.1296","volume":"9","author":"EAF Simoes","year":"2002","unstructured":"Simoes EAF, Groothuis JR (2002) Respiratory syncytial virus prophylaxis\u2014the story so far. Respir Med 9:S15\u2013S24","journal-title":"Respir Med"},{"key":"2849_CR34","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1874285801105010144","volume":"5","author":"C Sommer","year":"2011","unstructured":"Sommer C, Resch B, Sim\u00f5es EAF (2011) Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 5:144\u2013154","journal-title":"Open Microbiol J"},{"key":"2849_CR35","first-page":"55","volume":"154","author":"TP Stevens","year":"2000","unstructured":"Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM (2000) Respiratory syncytial virus and premature infants born at 32\u00a0weeks\u2019 gestation or earlier: hospitalization and economic implications of prophylaxis. Arch Pediatr Adolesc Med 154:55\u201361","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2849_CR36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1526-0542(12)00095-4","volume":"13","author":"SM Szabo","year":"2013","unstructured":"Szabo SM, Gooch KL, Bibby MM, Vo PG, Mitchell I, Bradt P, Levy AR (2013) The risk of mortality among young children hospitalized for severe respiratory syncytial virus infection. Paediatr Respir Rev 13:S1\u2013S8","journal-title":"Paediatr Respir Rev"},{"key":"2849_CR37","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1542\/peds.102.3.531","volume":"102","author":"The IMpact-RSV Study Group","year":"1998","unstructured":"The IMpact-RSV Study Group (1998) Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531\u2013537","journal-title":"Pediatrics"},{"key":"2849_CR38","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-014-0662-9","author":"G Thomas","year":"2015","unstructured":"Thomas G (2015) A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set. Eur J Health Econ. doi: 10.1007\/s10198-014-0662-9","journal-title":"Eur J Health Econ"},{"key":"2849_CR39","doi-asserted-by":"crossref","first-page":"e20152056","DOI":"10.1542\/peds.2015-2056","volume":"137","author":"P Thunqvist","year":"2016","unstructured":"Thunqvist P, Gustafsson PM, Schultz ES, Bellander T, Berggren-Bronstr\u00f6m E, Norman M, Wickman M, Mel\u00e9n E, Hallberg J (2016) Lung function at 8 and 16\u00a0years after moderate-to-late preterm birth: a prospective cohort study. Pediatrics 137:e20152056","journal-title":"Pediatrics"},{"key":"2849_CR40","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1542\/peds.2005-0620I","volume":"117","author":"MC Walsh","year":"2006","unstructured":"Walsh MC, Szefler S, Davis J, Allen M, Marter LV, Abman S, Blackmon L, Jobe A (2006) Summary proceedings from the bronchopulmonary dysplasia group. Pediatrics 117:S52\u2013S56","journal-title":"Pediatrics"},{"key":"2849_CR41","doi-asserted-by":"crossref","unstructured":"Wang D, Bayliss S, Meads C (2011) Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses. Health Technol Assess 15(5)","DOI":"10.3310\/hta15050"},{"key":"2849_CR42","doi-asserted-by":"crossref","unstructured":"Wang D, Cummins C, Bayliss S, Sandercock J, Burls A (2008) Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technol Assess 12(36)","DOI":"10.3310\/hta12360"},{"key":"2849_CR43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40121-014-0046-6","volume":"3","author":"C Wegzyn","year":"2014","unstructured":"Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M (2014) Safety and effectiveness of palivizumab in children at high risk of serious disease due to respiratory syncytial virus infection: a systematic review. Infect Dis Ther 3:133\u2013158","journal-title":"Infect Dis Ther"},{"key":"2849_CR44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00007691-200206000-00020","volume":"24","author":"HL Zaaijer","year":"2002","unstructured":"Zaaijer HL, Vandenbroucke-Grauls CM, Franssen EJ (2002) Optimum dosage regimen of palivizumab? Ther Drug Monit 24:444\u2013445","journal-title":"Ther Drug Monit"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-2849-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-017-2849-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-2849-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T06:15:52Z","timestamp":1601360152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-017-2849-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,20]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["2849"],"URL":"https:\/\/doi.org\/10.1007\/s00431-017-2849-4","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"type":"print","value":"0340-6199"},{"type":"electronic","value":"1432-1076"}],"subject":[],"published":{"date-parts":[[2017,1,20]]}}}